CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
Duvelisib +1 moredrug
Likely dose
Duvelisib 25 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04487886
NCT04487886Phase 2Completed
CompareCT.gov

Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection

Emory University·interventional·Posted Jul 27, 2020·Updated Apr 7, 2023

In Brief

A Phase 2 clinical trial evaluating Duvelisib and Placebo for COVID-19. Completed, enrolled 47 participants across 3 sites.

Detailed Summary

In this study, patients with severe coronavirus disease 2019 (COVID-19) infection will be randomized to receive duvelisib or a placebo. Participants will be enrolled at Emory University Hospital and will be identified and recruited by their treating physician and research team.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsVerastem, Inc.

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 27, 2020
Enrollment StartNov 18, 2020
Primary CompletionJun 10, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.9 years ago

Interventions

Duvelisibdrug

Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.

Placebodrug

A placebo to match duvelisib will be taken orally twice per day for 14 days.